1. Home
  2. MGNX

as 12-27-2024 2:39pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Founded: 2000 Country:
United States
United States
Employees: N/A City: Rockville
Market Cap: 257.3M IPO Year: 2013
Target Price: $7.17 AVG Volume (30 days): 477.0K
Analyst Decision: Hold Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.56 EPS Growth: N/A
52 Week Low/High: $2.95 - $21.88 Next Earning Date: 11-05-2024
Revenue: $141,329,000 Revenue Growth: 16.68%
Revenue Growth (this year): 174.73% Revenue Growth (next year): -50.72%

MGNX Daily Stock ML Predictions

Share on Social Networks: